

Effects of GSK v Teva Ripple after SCOTUS Denies Cert

PUBLICATIONS | LESS THAN 1 MIN READ

May 23, 2023


By: Ross Blau

Life Sciences IP Review

Axinn associate Ross Blau co-authored the *Life Sciences IP Review* article, “Effects of GSK v Teva Ripple after SCOTUS Denies Cert.”

Click [here](#) to access the publication. A subscription is required.

Related People



Ross E. Blau

Related Services

To subscribe to our publications, [click here](#).

Featured Insights

- GCR Live: Law Leaders Global 2025
SPEAKING ENGAGEMENT ANTITRUST
- Evidence for Trial Lawyers: Motions, Introducing Evidence, and Objections
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- NYC Bar Trade Secrets Symposium 2024: Navigating the Law of Trade Secrets and Restrictive Covenants
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Stakeholders 24th Annual CYOC Career Development Conference
SPONSORSHIP
- IAM Connect Patent Policy and Litigation Conference 2024
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- CompLaw 33rd Annual Advanced EU Brussels Conference
SPEAKING ENGAGEMENT
- Jason Murata Named a Profiles in Diversity Journal Diverse Lawyers Making a Difference Award Winner
AWARDS & RECOGNITIONS INTELLECTUAL PROPERTY
- AIC General Counsel Day 2024
SPEAKING ENGAGEMENT ANTITRUST
- ALM General Counsel Conference East 2024
SPEAKING ENGAGEMENT ANTITRUST
- Global M&A Antitrust Outlook: Trends Shaping Enforcement Strategies
SPEAKING ENGAGEMENT ANTITRUST

© 2024 Axinn, Veltrop & Harkrider LLP. All Rights Reserved